Letter to the Editor Regarding “Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age”
Crossref DOI link: https://doi.org/10.1007/s40121-022-00718-5
Published Online: 2022-11-14
Published Print: 2023-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Feemster, Kristen
Weiss, Thomas
Funding for this research was provided by:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Text and Data Mining valid from 2022-11-14
Version of Record valid from 2022-11-14
Article History
Received: 24 May 2022
Accepted: 19 October 2022
First Online: 14 November 2022